HLA-DOB

Across TCGA pan-cancer cohorts, HLA-DOB Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated HLA-DOB data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher HLA-DOB Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HLA-DOB expression acts as an unfavorable survival marker.

LIHC and ACC are the cancer types where HLA-DOB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

HLA-DOB–LIHC (DFS)

Open the LIHC breakdown →